Welcome to our dedicated page for Aerie Pharmaceut news (Ticker: AERI), a resource for investors and traders seeking the latest updates and insights on Aerie Pharmaceut stock.
Aerie Pharmaceuticals (NASDAQ: AERI) generates news coverage that matters to investors tracking the ophthalmology and biotechnology sectors. As a company focused on developing and commercializing treatments for glaucoma and other eye diseases, Aerie's announcements span clinical development milestones, commercial performance updates, and strategic corporate developments.
Investors following AERI stock monitor news for several key categories. Clinical trial updates provide insight into the company's pipeline progress for new formulations and indications. Quarterly earnings reports reveal prescription trends for Rhopressa and Rocklatan, the company's marketed glaucoma treatments. These financial disclosures help investors assess commercial execution and revenue trajectory.
The company also generates news through participation in major ophthalmology and healthcare investor conferences. Presentations at these events often provide management perspectives on market dynamics, competitive positioning, and strategic priorities that may not appear in formal SEC filings.
Regulatory announcements represent another important news category for Aerie. FDA interactions regarding new drug applications, label expansions, or manufacturing approvals can significantly impact the company's commercial outlook. For a company in the specialized ophthalmic pharmaceutical space, regulatory milestones often drive meaningful stock price movement.
Corporate development news, including partnership agreements for international distribution, licensing arrangements, and leadership appointments, provides context about the company's growth strategy and operational execution. For investors evaluating small-cap biotechnology companies, tracking these announcements helps build a complete picture of corporate progress beyond product-level metrics.
Bookmark this page to follow Aerie Pharmaceuticals news as the company navigates the competitive ophthalmology therapeutics market.
Aerie Pharmaceuticals (NASDAQ: AERI) announced that David A. Hollander, M.D., M.B.A., presented an overview of Aerie's globalization strategy at the Ophthalmology Innovation Summit European Innovation Showcase. The presentation highlighted Aerie's approach to expanding its glaucoma franchise and product candidates in Europe. Aerie is focused on developing first-in-class therapies for open-angle glaucoma and other ocular diseases. The company’s products include Rhopressa® and Rocklatan®, both aimed at reducing intraocular pressure in glaucoma patients.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has appointed Leon J. Atencia as the new Director of Regulatory Affairs, reporting to Emma Beausang. Atencia, who previously held a similar role at Revance Therapeutics, will manage clinical regulatory affairs and pharmacovigilance. As part of his compensation, he will receive 16,900 stock options vesting over four years, approved under Nasdaq Listing Rule 5635(c)(4). This strategic move aims to strengthen Aerie’s regulatory capabilities, critical for its product portfolio, including Rhopressa and Rocklatan.
Aerie Pharmaceuticals (NASDAQ:AERI) announced the appointment of Frank Estrada, Ed.D., as Director of Salesforce Training, effective immediately. Dr. Estrada will report to Evan Hockman and is tasked with developing training for Territory Sales Managers and the Sales Management Team across the U.S. He will receive 16,900 stock options that vest over four years, with 25% vesting after the first year. This award is part of an inducement under Nasdaq Listing Rule 5635(c)(4) and was approved by independent directors.
Aerie Pharmaceuticals (NASDAQ: AERI) announced that CEO Vicente Anido, Jr., Ph.D., will speak at the Raymond James Human Health Innovation Conference on June 22, 2021, at 1:20 p.m. ET. The discussion will cover an Aerie overview, business updates, sales figures, and the introduction of AR-6121, a new pipeline opportunity. Dr. Anido will also discuss the progress of Rhopressa development in Japan. The session will be webcast live on Aerie's website, with a replay available for 10 business days.
Aerie Pharmaceuticals (AERI) has completed patient enrollment for its first Phase 3 trial of netarsudil in Japan. The trial will compare the efficacy of netarsudil, administered once daily, to ripasudil, administered twice daily, over four weeks. A total of 245 patients were randomized. Results are expected by the end of 2021. This trial supports a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). Aerie has partnered with Santen Pharmaceutical for development and commercialization in Japan.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announced that Vicente Anido, Jr., Ph.D., will present at the Raymond James Human Health Innovation Conference on June 22, 2021, at 1:20 p.m. Eastern Time. The presentation will include an overview and business update of Aerie's operations, particularly its focus on first-in-class therapies for open-angle glaucoma and other ocular diseases. A live webcast of the discussion can be accessed on Aerie's website, with a replay available for 10 business days.
Aerie Pharmaceuticals (NASDAQ: AERI) announced that Vicente Anido, Jr., Ph.D., Chairman and CEO, will present at the Bank of America Securities 2021 Healthcare Conference on May 12, 2021, at 9:30 a.m. ET. The discussion will provide an overview of Aerie and a business update. The presentation will be webcast live on Aerie’s website, with a replay available for 10 business days. Aerie focuses on developing first-in-class therapies for open-angle glaucoma and ocular diseases, including their products Rhopressa® and Rocklatan®.
Aerie Pharmaceuticals (NASDAQ:AERI) reported first-quarter 2021 results showing 13% growth in net revenues and 11% increase in bottle volumes for its U.S. glaucoma franchise compared to the previous year. The company achieved a net revenue of $23 million with an average of $89 per bottle, the highest since 2019. Cash and investments totaled $208 million, with operational cash use down to $30 million from $42 million year-over-year. Aerie remains cautious about 2021 guidance due to pandemic uncertainties but stays aligned with analyst consensus.
Aerie Pharmaceuticals (NASDAQ: AERI) has completed patient enrollment for COMET-1, a Phase 2b clinical trial evaluating AR-15512, an ophthalmic solution for dry eye disease. The trial, initiated in October 2020, enrolled 369 patients across three treatment arms. Primary efficacy measures focus on ocular discomfort and tear production over three months. Aerie aims to address the unmet need of the 30 million dry eye sufferers in the U.S. with expectations to report topline results in Q3 2023. AR-15512 is protected by intellectual property rights until 2031.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) will release its first quarter 2021 financial results on May 5, 2021, after market close. A conference call to discuss these results will follow at 5:00 p.m. Eastern Time. Aerie focuses on ophthalmic therapies for glaucoma and related conditions, including its FDA-approved products, Rhopressa® and Rocklatan®. The company is committed to expanding its product offerings and targeting additional ophthalmic diseases.
